Compare Cytokinetics Inc (CYTK) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Emerson Electric Co. — how do they compare? Cytokinetics Inc trades at $62.72 (market cap $8.62B), while Emerson Electric Co. trades at $161.68 (market cap $88.72B). The key difference: Emerson Electric Co. is far larger — about 10.3× Cytokinetics Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Emerson Electric Co. for 81 Days on average.
| CYTK | EMR | |
|---|---|---|
Market Cap | $8.62B | $88.72B |
Volume | 2,594,626 | 2,355,255 |
Sector | Health | Industrials |
52-Week High | $87.26 | $164.38 |
52-Week Low | $54.76 | $123.30 |
Typical Hold Time | 19 Days | 81 Days |
Enterprise Value | $8.72B | $99.80B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Emerson Electric (EMR) trades at $161.13, up 1.2% today, with a bullish technical trend and strong quarterly earnings beats. The stock is supported by a 53.49% analyst buy consensus and a $165.90 price target. Revenue growth is steady, with 2025 revenue at $18.02B and net income of $2.29B, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. Recent news highlights momentum and Wall Street optimism, though valuation multiples like a P/E of 34.81 suggest premium pricing.
EMR's outlook is positive, driven by earnings momentum and analyst confidence, but risks include elevated valuation and debt levels. The stock offers growth potential with a dividend, yet investors face headwinds from competitive pressures and economic cycles. Upside to the consensus target implies modest gains, balancing fundamental strength with valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
